MindWalk Holdings (HYFT) EBITDA Margin Growth (3y) (2023 - 2026)

MindWalk Holdings (HYFT) EBITDA Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -204.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 828,504.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7,261.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.76 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -2,649.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,003.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 30,461.00
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -2.41 Mn

Historic Data

Download Data
DateValue
Apr 30, 2026 -47,743.00
Jan 31, 2026 8,797.00
Oct 31, 2025 -7.00
Jul 31, 2025 21.00
Apr 30, 2025 5,756.00
Jan 31, 2025 9.00
Oct 31, 2024 -5,273.00
Jul 31, 2024 -12,154.00
Apr 30, 2024 -9.23 Bn
Jan 31, 2024 -7,221.00
Oct 31, 2023 4,759.00
Jul 31, 2023 2,580.00